Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Coronavirus / COVID-19 Pandemic -- Ignore unavailable to you. Want to Upgrade?

To: Sam who wrote (2995)	5/20/2020 12:07:07 AM
From: Investor2	3 Recommendations Recommended By pheilman_ Stock Puppy Thomas M. Read Replies (1) \| Respond to of 22884

Hydroxychloroquine-treated patients were more severely ill at baseline than those who did not receive hydroxychloroquine So they gave the HCQ to the patients who were in worse shape and were about ready to die. It's almost like they wanted the HCQ to fail. Where's the zinc? The HCQ facilitates access of the zinc to the virus. Best wishes, I2

To: Sam who wrote (2995)	10/18/2021 3:00:05 PM
From: Thomas M.	Respond to of 22884

That study found the HCQ group was 4 times more likely to live than the control group. The authors massaged the data and use tricky language to create the exact opposite story! The authors chose “intubation or death” as their endpoint, which means the “intubation” event and the “death” event are considered equally. Would you rather be intubated or dead? If you dig into their data, you find that COVID patients who developed a respiratory failure turned out to be 4 times more likely to survive when treated with HCQ! The authors used the tricky language “HCQ was not associated with either a greatly lowered or an increased risk of the composite end point of intubation or death“ to make people think that HCQ reduces risk of neither intubation nor death. twitter.com Tom